A New Vaccine Targeted against Ductal Carcinoma In Situ
Abstract
Detection of Ductal Carcinoma In Situ (DCIS) increased dramatically with the advent of mammographic screening. Vaccines targeted against the HER-2/neu extracellular domain(ECD) protein might reduce the likelihood of progression to invasive disease for patients with high grade DCIS lesions. The vaccine strategy was tested in MMTV/c-neu transgenic mice that develop DCIS and tumors that overexpress rat neu ECD. Sixteen animals immunized with gD-neu and ten animals immunized with chicken albumin. Transgenic and non-transgenic developed high serum anti-neu antibody titers after vaccination. Transgenic animals immunized with CFA/neu-ECD had a marked statistically significant decrease in the rate and number of tumors developed by 52 weeks of age when compared to transgenics that were immunized with controls (p>0.005). Lymphocytes from nodes of transgenic and non-transgenic animals immunized with neu-ECD proliferated four fold in response to in vitro culture with neu-ECD but not in response to Her-2(human). MMTV neu transgenic mice develop an immune response and decreased tumor growth after vaccination with a 'self' protein. Results demonstrate the potential of a vaccine strategy for the prevention of tumor formation in patients at risk of forming HER-2/neu based tumors.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 1997
- Accession Number
- ADB228198
Entities
People
- Laura J. Esserman
Organizations
- University of California, San Francisco